IP Library Granted Patent US 8,530,404
Granted Patent B2
US 8,530,404 · App. 11/455,199 · Granted Sep 10, 2013

Compounds and methods for treatment of cancer

Inventors: Todd W. Seeley (Moraga, CA); David Y. Liu (Palo Alto, CA); Stephen J. Klaus (San Francisco, CA)
Assignee: FibroGen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,530,404
App. No.
11/455,199
Granted
Sep 10, 2013
Kind
B2
Abstract

The invention relates to methods and compounds for treating or preventing cancer. Methods for treating or preventing cancer, for inhibiting tumor growth, reducing tumor volume, inhibiting tumor progression, inhibiting metastasis, and improving survival are provided herein.

Claims (12)

1. A method for treating cancer in a subject in need, the method comprising the steps of: (a) identifying a subject having cancer; (b) administering to the subject an effective amount of an agent that stabilizes HIFα, wherein the agent is a 2-oxoglutarate mimetic that inhibits HIF prolyl hydroxylase activity, thereby treating cancer in the subject; and (c) monitoring the progression of cancer in the treated subject.

2. The method of claim 1 , wherein the subject is a mammalian subject.

3. The method of claim 1 , wherein the subject is a human subject.

4. A method for inducing an anti-tumor effect in a subject having a tumor, the method comprising the steps of: (a) administering to the subject an effective amount of an agent that stabilizes HIFα, wherein the agent is a 2-oxoglutarate mimetic that inhibits HIF prolyl hydroxylase activity, thereby inducing an anti-tumor effect in the subject; and (b) measuring the anti-tumor effect in the subject.

5. The method of claim 1 , wherein the administering to the subject an effective amount of the agent comprises administering the agent orally, systemically, intravenously, or by injection.

6. The method of claim 1 , wherein the method further comprises administering to the subject one or more chemotherapeutic agent.

7. The method of claim 4 , wherein the subject is a mammalian subject.

8. The method of claim 4 , wherein the subject is a human subject.

9. The method of claim 4 , wherein the administering to the subject an effective amount of the agent comprises administering the agent orally, systemically, intravenously, or by injection.

10. The method of claim 4 , wherein the method further comprises administering to the subject one or more chemotherapeutic agent.

11. The method of claim 4 , wherein the anti-tumor effect is selected from the group consisting of reducing tumor volume, inhibiting tumor growth, inhibiting tumor progression, altering metabolic activity in a tumor, inducing quiescence in a tumor, inhibiting or reducing tumor invasiveness, inhibiting or reducing tumor angiogenesis or tumor neovascularization, and reducing tumor weight.

12. A method for treating cancer in a subject in need, the method comprising the steps of: (a) identifying a subject having cancer; (b) administering to the subject an effective amount of an agent that inhibits HIF prolyl hydroxylase activity, and wherein the agent is a 2-oxoglutarate mimetic, thereby treating cancer in the subject; and (c) monitoring the progression of cancer in the treated subject.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: FIBROGEN, INC.
Reel/Frame 072785/0760 →
SECURITY INTEREST Recorded May 1, 2023
From: FIBROGEN, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 063504/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2010
From: SEELEY, TODD W.; LIU, DAVID Y.; KLAUS, STEPHEN J.
To: FIBROGEN, INC.
Reel/Frame 024281/0451 →
Continuity (2)
Provisional Application 60691006 · Jun 15, 2005
Related Publication 20070004627A1 · Jan 4, 2007